Vt-101
Phase 1
Vt-101 is one of 8 therapeutic programs targeting Epithelial Ovarian Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
7 competitors in Epithelial Ovarian Cancer
#DrugCompanyPhaseTrials
1BL-B01D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
BL-M07D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
AZD5335
AstraZenecaPhase 3
Keytruda
Merck & Co.Preclinical
Neoadjuvant Chemotherapy
JJapan Clinical Oncology Group
Preclinical
SKB264
SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Preclinical
Rina-S
GenmabPreclinical
Vt-101
MMichael J. Goodheart
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Vt-101. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- MMichael J. Goodheart